Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Technology appraisal
Summary (source: NICE)
Reference: TA391
Type: Technology appraisal
Published: 25 May 2016
Last updated: 24 August 2016
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel is technology appraisal TA391, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 25 May 2016. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.